The use of the PPARγ agonist pioglitazone has also been combined with colesevelam (2014): 562 T2D patients with suboptimal glycemic control were randomized to colesevelam 3.8 g/day or placebo added to existing stable pioglitazone-based therapy [83]. Here, PPARG is linked to type 2 diabetes mellitus.